COMP <GO>
OCS vs CBIO // NET PROFIT MARGIN
Oculis Holding AG (NASDAQ) VS. Crescent Biopharma Inc. (NASDAQ) • 15-METRIC TALLY: OCS 0
— CBIO 2
■ METRIC PARITY
LAST: $8.24 (+3.26%) • MKT CAP: $507.5M
net-margins
—
LAST: $14.07 (+4.22%) • MKT CAP: $522.6M
net-margins
1.40%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (OCS VS. CBIO)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | OCS | CBIO | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | — | -35.00% | — | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | — | -13.86% | — | TIE | /fcf-yield <GO> |
| Operating Margin | — | -60.00% | — | TIE | /operating-margins <GO> |
| Net Profit Margin ACTIVE | — | 1.40% | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | — | — | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | 6.36 | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | — | 3/9 | — | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 45.6 | 46.1 | -0.46 | CBIO | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $507.5M | $522.6M | -$15.1M | CBIO | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | OCS REV | CBIO REV | OCS GROSS % | CBIO GROSS % | OCS FCF | CBIO FCF |
|---|---|---|---|---|---|---|
| FY 2025 | — | $10.8M | — | — | — | -$72.5M |
| FY 2024 | — | $0 | — | — | — | -$31.1M |
| FY 2023 | — | $0 | — | — | — | -$34.9M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
OCS // BETA —
CBIO // BETA —